| Literature DB >> 30783389 |
Tomasz Nowikiewicz1,2, Adam Nowak3, Magdalena Wiśniewska4,5, Michał Wiśniewski6, Magdalena Nowikiewicz7, Wojciech Zegarski1,2.
Abstract
INTRODUCTION: Properly planned and performed diagnostic tests allow the optimal treatment option to be chosen for the patient. They also allow qualification for the correct surgical procedure. AIM OF THE STUDY: In this study we evaluated the clinical value of preoperative ultrasound scan (USS) testing performed during primary disease staging in patients with early breast cancer qualified to sentinel lymph node biopsy (SLNB).Entities:
Keywords: breast cancer; conserving treatment; sensitivity; sentinel node; specificity; ultrasonography
Year: 2018 PMID: 30783389 PMCID: PMC6377422 DOI: 10.5114/wo.2018.82644
Source DB: PubMed Journal: Contemp Oncol (Pozn) ISSN: 1428-2526
Fig. 1Study qualification scheme
Fig. 2Results of preoperative USS examination of axillary lymph nodes and pathological assessment of sentinel nodes removed during SLNB
Study patients – clinical and pathological features
| Clinical and pathological features | Correct result of preoperative USS (TN + TP) | Incorrect result of preoperative USS (FN + FP) | |||
|---|---|---|---|---|---|
| % | % | ||||
| Age | |||||
| < 40 years | 9 | 6.6 | 2 | 5.6 | 0.896 |
| 40 to 60 years | 63 | 46.3 | 13 | 36.1 | 0.765 |
| > 60 years | 64 | 47.1 | 21 | 58.3 | 0.657 |
| BMI | |||||
| Normal (18.5–24.9) | 47 | 34.6 | 12 | 33.3 | 0.876 |
| Overweight (25–29.9) | 52 | 38.2 | 13 | 36.1 | 0.764 |
| Obesity (≥ 30) | 37 | 27.2 | 11 | 30.6 | 0.795 |
| Palpable tumour | 79 | 58.1 | 24 | 66.7 | 0.205 |
| Tumour size (in USS scan) | |||||
| T1a | 14 | 10.7 | – | -19.4 | -0.322 |
| T1b | 37 | 28.2 | 7 | 58.3 | 0.687 |
| T1c | 66 | 50.4 | 21 | 22.2 | 0.778 |
| T2 | 14 | 10.7 | 8 | – | – |
| T3 | – | – | – | – | – |
| No data | 5 | – | – | ||
| Tumour size (pathological report – pT) | |||||
| T0 (after BMU) | 2 | 1.5 | – | – | – |
| T1mic | 4 | 3 | 1 | 2.8 | 0.288 |
| T1a | 3 | 2.2 | – | – | – |
| T1b | 23 | 17 | 3 | 8.3 | 0.657 |
| T1c | 77 | 57 | 19 | 52.8 | 0.864 |
| T2 | 26 | 19.3 | 13 | 36.1 | 0.764 |
| T3 | – | – | – | – | – |
| T4 | 1 | 0.6 | – | – | – |
| Histological grading | |||||
| G1 | 12 | 9.2 | 3 | 8.6 | 0.674 |
| G2 | 95 | 72.5 | 24 | 68.6 | 0.453 |
| G3 | 24 | 18.3 | 8 | 22.9 | 0.452 |
| no data | 5 | – | 1 | – | – |
| Histological type | |||||
| ductal carcinoma | 115 | 84.6 | 32 | 88.9 | 0.673 |
| lobular carcinoma | 18 | 13.2 | 3 | 8.3 | 0.564 |
| another invasive type | 3 | 2.2 | 1 | 2.8 | 0.765 |
| ER positive | 116 | 85.3 | 28 | 77.8 | 0.345 |
| ER negative | 20 | 14.7 | 8 | 22.2 | 0.632 |
| PR positive | 116 | 85.3 | 28 | 77.8 | 0.433 |
| PR negative | 20 | 14.7 | 8 | 22.2 | 0.245 |
| HER2 positive | 19 | 14 | 2 | 5.6 | 0.236 |
| HER2 negative | 117 | 86 | 34 | 94.4 | 0.435 |
| Ki-67 index | |||||
| 0–14% | 37 | 38.1 | 17 | 60.7 | 0.534 |
| 15–30% | 49 | 50.5 | 6 | 21.4 | 0.653 |
| 31–45% | 4 | 4.1 | 4 | 14.3 | 0.247 |
| above 45% | 7 | 7.2 | 1 | 3.6 | 0.543 |
| no data | 39 | – | 8 | – | – |
| Biological type | |||||
| luminal A | 37 | 30.3 | 17 | 50 | 0.534 |
| luminal B HER2 negative | 56 | 45.9 | 8 | 23.5 | 0.653 |
| luminal B HER2 positive | 10 | 8.2 | 1 | 2.9 | 0.435 |
| HER2 positive | 9 | 7.4 | 1 | 2.9 | 0.678 |
| triple negative | 10 | 8.2 | 7 | 20.6 | 0.634 |
| no data | 14 | – | 2 | – | – |
| All | 136 | 100 | 36 | 100 | |
TN – negative result; TP – positive result; FN – false negative result; FP – false positive result; n – number of patients; p – significance level; BMI – body mass index; BMU – Mammotome biopsy; ER – oestrogen receptor; PR – progesterone receptor; HER2 – HER2 receptor